ArticleScientific reports2015
A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed.
- Meta-signature LncRNAs serve as novel biomarkers for colorectal cancer: integrated bioinformatics analysis, experimental validation and diagnostic evaluation.Scientific reports · 2017Trial
- Article
- KDM7A-DT induces genotoxic stress, tumorigenesis, and progression of p53 missense mutation-associated invasive breast cancer.Frontiers in oncology · 2024Article
- An anoikis-related lncRNA signature is a useful tool for predicting the prognosis of patients with lung adenocarcinoma.Heliyon · 2023Article
- Comprehensive research into prognostic and immune signatures of transcription factor family in breast cancer.BMC medical genomics · 2023Article
- The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer.International journal of molecular sciences · 2023Review
- Long non-coding RNA FOXD3-AS1 silencing exerts tumor suppressive effects in nasopharyngeal carcinoma by downregulating FOXD3 expression via microRNA-185-3p upregulation.Cancer gene therapy · 2021Article
- Identification of a Transcription Factor Signature That Can Predict Breast Cancer Survival.Computational and mathematical methods in medicine · 2021Article
- Developing ZNF Gene Signatures Predicting Radiosensitivity of Patients with Breast Cancer.Journal of oncology · 2021Article
- A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer.Journal of cellular and molecular medicine · 2020Article
- Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.RNA biology · 2020Article
- An immune-related prognostic signature for predicting breast cancer recurrence.Cancer medicine · 2020Article
- FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction.Cell death & disease · 2020Article
- lncRNAs-mRNAs Co-Expression Network Underlying Childhood B-Cell Acute Lymphoblastic Leukaemia: A Pilot Study.Cancers · 2020Article
- Bioinformatics analysis of prognosis-related long non-coding RNAs in invasive breast carcinoma.Oncology letters · 2020Article
- Overexpression of a Long Non-Coding RNA BC037916 is Associated with Pancreatic Tumorigenesis and Poor Prognosis.OncoTargets and therapy · 2020Article
- Genomic Profiling Comparison of GermlineFrontiers in oncology · 2020Article
- Integrative analysis of miRNA and mRNA expression profiles reveals a novel mRNA/miRNA signature to improve risk classification for patients with gastric cancer.Oncology letters · 2019Article
- Bioinformatic analysis of long non-coding RNA-associated competing endogenous RNA network in adrenocortical carcinoma.Translational cancer research · 2019Article
- Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) have been implicated in a variety of biological processes, and dysregulated lncRNAs have demonstrated potential roles as biomarkers and therapeutic targets for cancer prognosis and treatment. In this study, by repurposing microarray probes, we analyzed lncRNA expression profiles of 916 breast cancer patients from the Gene Expression Omnibus (GEO). Nine lncRNAs were identified to be significantly associated with metastasis-free survival (MFS) in the training dataset of 254 patients using the Cox proportional hazards regression model. These nine lncRNAs were then combined to form a single prognostic signature for predicting metastatic risk in breast cancer patients that was able to classify patients in the training dataset into high- and low-risk subgroups with significantly different MFSs (median 2.4 years versus 3.0 years, log-rank test p < 0.001). This nine-lncRNA signature was similarly effective for prognosis in a testing dataset and two independent datasets. Further analysis showed that the predictive ability of the signature was independent of clinical variables, including age, ER status, ESR1 status and ERBB2 status. Our results indicated that lncRNA signature could be a useful prognostic marker to predict metastatic risk in breast cancer patients and may improve upon our understanding of the molecular mechanisms underlying breast cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.